Future of Nektar Therapeutics | Quantumrun

Future of Nektar Therapeutics

Biopharmaceutical company Nektar Therapeutics created the world’s first inhalable non-injectable insulin, called Exubera. The drug was awarded the bronze award for its breakthrough and seen as the most innovative diabetes medicine of 2006 in Germany. Founded in 1990 and based in San Francisco, Calif., the company creates its own pipeline of potential drugs that can be used in areas such as oncology, pain and immunology. It supplies its products to a variety of pharmaceutical companies like Affymax, Amgen and Pfizer.

Home Country: 
United States
Industry: 
Biopharmaceutical
Industry vulnerability to disruption: 

<p>Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:</p>

<p>*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.<br />
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.<br />
*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.<br />
*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.<br />
*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.<br />
*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.</p>

Total patents held: 
351
Number of patents field last year: 
2
Ranking List: 
604
Ranking List: 
2017 Quantumrun Global 1000
397
Ranking List: 
2017 Quantumrun US 500
68
Ranking List: 
2017 Quantumrun Silicon Valley 100
Market Revenue Country: 
Market country 
Europe
Revenue from country 
0.76
Prod/Serv name revenue: 
Prod/Serv name: 
License, collaboration and other revenue
Prod/Serv revenue: 
165604000
Prod/Serv name: 
Product sales
Prod/Serv revenue: 
40155000
Prod/Serv name: 
Non cash royalty revenue
Prod/Serv revenue: 
22058000
Founded: 
1990
Company Name: 
Nektar Therapeutics
Revenue: 
165436000
3y average revenue: 
198975667
Operating expenses: 
278291000
3y average expenses: 
251879333
Company profile data note: 
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
Global employee count: 
468
Domestic employee count: 
392
Number of domestic locations: 
2
Funds in reserve: 
59640000
Investment into R&D: 
203801000
create term: 
#604 | 2017 Quantumrun Global 1000
#397 | 2017 Quantumrun US 500
#68 | 2017 Quantumrun Silicon Valley 100

Biopharmaceutical company Nektar Therapeutics created the world’s first inhalable non-injectable insulin, called Exubera. The drug was awarded the bronze award for its breakthrough and seen as the most innovative diabetes medicine of 2006 in Germany. Founded in 1990 and based in San Francisco, Calif., the company creates its own pipeline of potential drugs that can be used in areas such as oncology, pain and immunology. It supplies its products to a variety of pharmaceutical companies like Affymax, Amgen and Pfizer.

Home country:
United States
Sector:
Pharmaceuticals
Industry:
Biopharmaceutical
Founded:
1990
Global employee count:
468
Domestic employee count:
392

Financial Health

Revenue
$165,436,000 USD
3y average revenue
$198,975,667 USD
Operating expenses
$278,291,000 USD
3y average expenses
$251,879,333 USD
Funds in reserve
$59,640,000 USD
#1 Market country
Europe
% of revenue from country #1
0.76%

Asset Performance

#1 Product/Service/Dept. name
License, collaboration and other revenue
#1 Product/Service revenue
$165,604,000 USD
#2 Product/Service/Dept. name
Product sales
#2 Product/Service revenue
$40,155,000 USD
#3 Product/Service/Dept. name
Non cash royalty revenue
#3 Product/Service revenue
$22,058,000 USD

Innovation assets and Pipeline

Investment into R&D
$203,801,000 USD
Total patents held
351
Number of patents field last year
2
All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.

Disruption Vulnerability

Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.

*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.

*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.

*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.

*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.

*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.